Value-based pricing of pharmaceuticals in Canada [electronic resource] : opportunities to expand the role of health technology assessment? / Don Husereau, Chris G. Cameron.
The rate of spending on health in Canada is rising faster than the rate of economic growth, creating concerns about the sustainability of Canada's publicly funded healthcare systems. Expenditures on drugs is one of the fastest-growing areas, representing an average of 6.3% compounded annual growth of real per capita healthcare expenditures in the last decade. Reimbursement for drugs has risen steadily over the past 10 years--in 2010, for example, spending on drugs reached $31.1 billion, amounting to 16.3% of total healthcare spending.
Record details
- Physical Description: 1 electronic text (v, 34 p.) : digital file.
- Publisher: Ottawa, Ont. : Canadian Health Services Research Foundation, 2011
Content descriptions
General Note: | "December 2011." Issued as part of the desLibris documents collection. |
Bibliography, etc. Note: | Includes bibliographical references (p. 28-32). |
Formatted Contents Note: | Context -- Health technology assessment (HTA ), value and price -- Current and future role of HTA in pharmaceutical price negotiation -- Challenges of implementing a value-based pricing system -- Moving forward with HTA-based price negotiation in Canada -- Conclusions and recommendations -- References -- Appendix A: List of participants in semi-structured interviews -- Appendix B: Semi-structured interview guide. |
System Details Note: | Mode of access: World Wide Web. |
Search for related items by subject
Genre: | Electronic books. |